First in Human Study to Evaluate the Safety and Tolerability of EYP-1901 in Patients With Wet Age Related Macular Degeneration (wAMD)
Public ClinicalTrials.gov record NCT04747197. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1, Multicenter, Prospective, Open-Label, Dose Escalation Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), in Subjects With Wet AMD
Study identification
- NCT ID
- NCT04747197
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- EyePoint Pharmaceuticals, Inc.
- Industry
- Enrollment
- 17 participants
Conditions and interventions
Conditions
Interventions
- EYP-1901 Drug
Drug
Eligibility (public fields only)
- Age range
- 50 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 19, 2021
- Primary completion
- May 10, 2022
- Completion
- May 10, 2022
- Last update posted
- Jul 18, 2023
2021 – 2022
United States locations
- U.S. sites
- 11
- U.S. states
- 7
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| EyePoint Investigational Site | Phoenix | Arizona | 85053 | — |
| EyePoint Investigational Site | Beverly Hills | California | 90211 | — |
| EyePoint Investigative Site | Mountain View | California | 94040 | — |
| EyePoint Investigational Site | Oxnard | California | 93036 | — |
| EyePoint Investigational Site | Melbourne | Florida | 32901 | — |
| EyePoint Investigational Site | St. Petersburg | Florida | 33711 | — |
| EyePoint Investigational Site | Springfield | Massachusetts | 01107 | — |
| EyePoint Investigative Site | Asheville | North Carolina | 28803 | — |
| EyePoint Investigational Site | Philadelphia | Pennsylvania | 19107 | — |
| EyePoint Investigational Site | Abilene | Texas | 79606 | — |
| EyePoint Investigational Site | Austin | Texas | 78705 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04747197, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 18, 2023 · Synced Jun 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04747197 live on ClinicalTrials.gov.